---
title: "Genmab’s Strong Financial Performance and Promising Pipeline Reinforce Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264802515.md"
description: "William Blair analyst Matt Phipps has maintained a Buy rating on Genmab (GMAB) stock as of October 27, citing strong financial performance and a promising pipeline. The company reported third-quarter revenues that surpassed expectations, driven by increased royalties and product sales. Despite a slight miss in Epkinly sales, overall guidance remains stable, with significant catalysts expected by late 2025 and into 2026, including potential FDA approvals. Phipps has a 44.98% success rate on stock recommendations."
datetime: "2025-11-07T07:25:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264802515.md)
  - [en](https://longbridge.com/en/news/264802515.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264802515.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264802515.md) | [繁體中文](https://longbridge.com/zh-HK/news/264802515.md)


# Genmab’s Strong Financial Performance and Promising Pipeline Reinforce Buy Rating

William Blair analyst Matt Phipps has reiterated their bullish stance on GMAB stock, giving a Buy rating on October 27.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Matt Phipps has given his Buy rating due to a combination of factors including Genmab’s strong financial performance and promising pipeline developments. The company reported third-quarter revenues that exceeded expectations, driven by higher royalties and product sales, which indicates robust financial health and steady revenue growth.  
Furthermore, despite a slight miss in Epkinly sales, the overall guidance remains intact, and the company is on track with its late-stage pipeline developments. With several significant catalysts anticipated towards the end of 2025 and into 2026, including potential FDA approvals and pivotal trial readouts, Genmab’s pipeline holds the potential for long-term revenue growth, reinforcing the Buy rating.

Phipps covers the Healthcare sector, focusing on stocks such as Merus, Upstream Bio, Inc., and Bristol-Myers Squibb. According to TipRanks, Phipps has an average return of 2.0% and a 44.98% success rate on recommended stocks.

### Related Stocks

- [Genmab A/S (GMAB.US)](https://longbridge.com/en/quote/GMAB.US.md)

## Related News & Research

- [Genmab Updates Articles of Association, Expands Capital Issuance Flexibility](https://longbridge.com/en/news/280180559.md)
- [Genmab (CPSE:GMAB) Valuation Check As Amlenetug Clinical Progress Draws Fresh Investor Attention](https://longbridge.com/en/news/280355648.md)
- [3 Best ETFs to Invest In, According to AI Analyst, 03/31/2026](https://longbridge.com/en/news/281217554.md)
- [3 discounted AI stocks to buy now for long-term growth](https://longbridge.com/en/news/280929951.md)
- [Rezolve AI 2026 Guidance Suggest 700% Revenue Growth, Analyst Says](https://longbridge.com/en/news/281218944.md)